Macquarie Group Ltd. cut its stake in shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) by 46.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 59,128 shares of the biotechnology company’s stock after selling 51,875 shares during the period. Macquarie Group Ltd.’s holdings in Ironwood Pharmaceuticals were worth $886,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in IRWD. Sarissa Capital Management LP purchased a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at $24,733,000. Senzar Asset Management LLC raised its stake in Ironwood Pharmaceuticals by 185.8% during the 4th quarter. Senzar Asset Management LLC now owns 1,448,800 shares of the biotechnology company’s stock valued at $21,718,000 after buying an additional 941,800 shares during the last quarter. Broderick Brian C raised its stake in Ironwood Pharmaceuticals by 237.1% during the 4th quarter. Broderick Brian C now owns 487,065 shares of the biotechnology company’s stock valued at $7,301,000 after buying an additional 342,589 shares during the last quarter. State of Wisconsin Investment Board raised its stake in Ironwood Pharmaceuticals by 15.8% during the 4th quarter. State of Wisconsin Investment Board now owns 846,800 shares of the biotechnology company’s stock valued at $12,694,000 after buying an additional 115,800 shares during the last quarter. Finally, Chicago Equity Partners LLC raised its stake in Ironwood Pharmaceuticals by 80.9% during the 4th quarter. Chicago Equity Partners LLC now owns 213,680 shares of the biotechnology company’s stock valued at $3,203,000 after buying an additional 95,545 shares during the last quarter.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 18th. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, February 11th. ValuEngine lowered shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 29th. Finally, Bank of America lowered shares of Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and decreased their target price for the company from $20.00 to $15.00 in a research note on Friday, January 5th. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $17.29.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. Ironwood Pharmaceuticals had a negative net margin of 39.20% and a negative return on equity of 2,073.20%. The firm had revenue of $94.20 million during the quarter, compared to the consensus estimate of $88.86 million. During the same quarter in the previous year, the firm posted ($0.12) EPS. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. sell-side analysts forecast that Ironwood Pharmaceuticals will post -0.46 earnings per share for the current fiscal year.
In other news, insider Mark G. Currie sold 60,000 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $15.45, for a total transaction of $927,000.00. Following the completion of the sale, the insider now owns 835,000 shares of the company’s stock, valued at approximately $12,900,750. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Gina Consylman sold 3,594 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $14.66, for a total transaction of $52,688.04. Following the sale, the chief financial officer now directly owns 59,125 shares of the company’s stock, valued at approximately $866,772.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,728 shares of company stock valued at $1,024,732. Insiders own 7.63% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3340171/macquarie-group-ltd-decreases-holdings-in-ironwood-pharmaceuticals-irwd.html.
Ironwood Pharmaceuticals Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.